Download - Fibroid2
![Page 1: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/1.jpg)
Rajesh Varma MA PhD MRCOGConsultant Obstetrician and Gynaecologist
Guy’s and St.Thomas’ NHS Foundation Trust
1415-1515: Tue 25th November 2008Hot Topics in Clinical Practice
Postgraduate Centre, Gassiot House, St.Thomas’ Hospital 1
![Page 2: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/2.jpg)
Fibroids
Benign, but have 0.2% risk of malignant transformationOccur in 10% of HMBRecurrence risk after myomectomy (10% at 5 years)
May undergo degeneration (hyaline, fatty, Red during pregnancy)May become acutely painful (torsion, haemorrhage, sepsis, degeneration)
2
![Page 3: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/3.jpg)
Wamsteker K et al. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993; 82(5):736-740.
3
![Page 4: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/4.jpg)
Do all women with fibroids need treatment?1. Asymptomatic
2. Abnormal Uterine Bleeding (AUB)
Menorrhagia, anaemia
Pelvic pressure effects (renal tract-ureter, bladder)
Pelvic Pain
3. Improve fertility (reduce risk of miscarriage)
4
![Page 5: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/5.jpg)
5
![Page 6: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/6.jpg)
Myomectomy and AUBRemoval of the intracavity component of the submucous
fibroid improves AUB (70-80% improvement)
(Level II evidence)
Parker WH. Uterine myomas: management. Fertil Steril. 2007 Aug;88(2):255-71. 2007 Jul 20.
Varma R et al. Hysteroscopic myomectomy for menorrhagia using Versascope™ bipolar system: efficacy and prognostic factors at a minimum of one year follow up. In Press 2008, EJOG.
Paradox: Post operative adhesions may cause pain and infertility
6
![Page 7: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/7.jpg)
Klatsky PC et al. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol. 2008 Apr;198(4):357-66.
ASRM. Myomas and reproductive function. Fertility and Sterility, Volume 90, Issue 5, Supplement 1, November 2008, Pages S125-S130
Pritts EA et al. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2008 Mar 11
Removal of the intracavity component of the submucous f ibroid improves fert i l i ty (RR 1.72; 95% CI 1.13-2.58)
Subserosal fibroids do not affect fertility outcome
Intramural fibroids appear to decrease fertility, but the results of therapy are unclear.
(Level II evidence)
Myomectomy and Fertility
7
![Page 8: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/8.jpg)
NICE (Jan 2007) HMB
8
![Page 9: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/9.jpg)
MEDICAL THERAPIESFIBROID SIZE AUB FERTILITY
NSAIDs No effect fibroid size
Decrease 30% No effect
COC No data Decrease 20-30% Contraceptive
GNRHa * (3m-6m)
Decrease 30%Decrease uterine volume by 35%
Decrease >80% Contraceptive
Progestins
LARC
LNG-IUSMirena(uterine cavity<12cm)
Decrease 30%
Decrease uterine volume by 35%
Decrease>60%
Breakthrough bleeding
systemic side effects
Contraceptive
9
![Page 10: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/10.jpg)
GnRHaSide effects Experienced by 95%Hot flushes; vaginal dryness; frontal headaches10% women stop treatment due to side effectsOsteopenia: >6m use
Prevented with add-back (tibilone, raloxifene)
Suitable women?
1. 3-4 m prior to myomectomy (hysteroscopic, abdominal) or hysterectomy (anaemia, transfusion, avoid midline entry) (concern: recurrence of small myomas & surgical dissection)
2. Late perimenopause as “short-term” treatment (+/- add-back)
10
![Page 11: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/11.jpg)
NEW MEDICAL THERAPIES (UNDER TRIAL)
FIBROID SIZE AUB FERTILITY
GnRH antagonist Ganirelix(sc daily/6m)
Decrease 30-40% Decrease Contraceptive
Mifepristone(5mg daily/6m)
Decrease 40%Decrease uterine size 40%
Decrease(risk of endometrial hyperplasia)
Contraceptive
SPRMAsoprisnil(10mg daily/6m)
Decrease Decrease Contraceptive
Aromatase Inhibitors
Decrease Decrease Contraceptive
11
![Page 12: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/12.jpg)
Fibroids >3cm size
Fertility preserved
Contraceptive
Fertility is potentiallyretained
12
![Page 13: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/13.jpg)
Abdominal Myomectomy>80% improvement in AUBVery low conversion rate to hysterectomyComparable risk to hysterectomy (organ damage,
transfusion)Correct pre-operative anaemia (EPO, GnRHa)TourniquetTransverse uterine incisions (parallel to arcuate vessels)Anti-adhesion : limit number of uterine incisions, anti-
adhesion barrier, drainageRe-treatment rates after myomectomy over 5-10 years
(symptom +/-fibroid recurrence):
10% single myomectomy vs. 25% multiple myomectomy
13
![Page 14: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/14.jpg)
Abdominal Myomectomy
14
![Page 15: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/15.jpg)
Value of adhesion prevention ?
15
![Page 16: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/16.jpg)
Hysteroscopic Myomectomy
Versapoint®Resectoscope
16
![Page 17: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/17.jpg)
Hysteroscopic myomectomy
Fibroid size Intracavity fibroid 90-100%
AUB Decrease >80%
Fertility Increase 40-60%
Secondary treatment (2yr 10%; 5yr 30%)
Complication rate 1-2% Uterine perforationSepsis; intrauterine adhesionsHaemorrhageHyponatraemic fluid overload
Additional treatment May be combined with endometrial resection or ablation-improved effect on AUB
17
![Page 18: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/18.jpg)
Hysteroscopic myomectomy:New developmentsUse of pre-operative GnRHa 3-4m
Improved video instrumentation
Bipolar resectoscopes: virtually eliminates risk of hyponatraeimc fluid overload syndrome
Outpatient microhysteroscopy and Versapoint®- concept of One Stop See-and-Treat gynaecology clinic
18
![Page 19: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/19.jpg)
3.5mm diameter disposable outer sheath 19
![Page 20: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/20.jpg)
Video clip Outpatient fibroid resection
20
![Page 21: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/21.jpg)
New Interventional Technologies
Treatment in women with fibroid-related symptoms and not desiring future fertility
Uterine artery embolization (UAE)Magnetic resonance image-guided transcutaneous
focused ultrasound for uterine fibroids (MRgFUS)Magnetic resonance (MR) image-guided percutaneous
laser ablation of uterine fibroidsLaparoscopic or transvaginal uterine artery occlusionLaparoscopic cryomyolysis
21
![Page 22: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/22.jpg)
Aims: New Interventional TechnologiesImprovement in AUB, fertility and & QoL Avoid risks of major surgery (e.g. quicker recovery)Safety (lower complication rate)Sustained benefit (low re-treatment rate)Cost-effective
Insufficient evidence:
RCTs with long term data are lacking22
![Page 23: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/23.jpg)
NICE (Oct 2004)
Audit and review clinical outcomes of allpatients having UAE.
Data should besubmitted to the British Society of Interventional Radiology registry (www.bsir.org).
23
![Page 24: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/24.jpg)
•Both uterine arteries are blocked by Interven. Radiol.•Contraindications :active genitourinary infection, genital tract malignancy•Relative contraindications:submucous myomas (check hysteroscopy prior to UAE), pedunculated myomas, recent GnRHa, previous UAE, postmenopausal status
Uterine artery embolisation (UAE)
24
![Page 25: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/25.jpg)
UAEFibroid size Reduced 30-50%
AUB Improved (>80% satisfaction)- sustained over 5yr
Fertility Reported case series: obstetric outcome uncertain
Secondary treatment
20-30% within 5yr
Complication rate
1-2w recovery back to work10-15% persistent vaginal discharge5% Post embolization syndrome (pain, fever, nausea, vomiting)10-15% risk premature ovarian failure (especially>45y)20% intra-abdominal adhesions<1% uterine necrosis/sepsis; death 1/10,000
•Gupta, JK et al. Uterine artery embolization for symptomatic uterine fibroids. Cochrane 2008. •G. Tropeano et al.Non-surgical management of uterine fibroids. Hum Reprod Update 2008;14(3): 259 – 274.•Agdi et al. Intraabdominal adhesions after uterine artery embolization. AJOG, Volume 199, Issue 5, November 2008, Pages 482.e1-482.e3 25
![Page 26: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/26.jpg)
NICE (Sept 2007)
Audit and review clinical outcomes of allpatients having MRgFUS.
Data should besubmitted to the British Society of Interventional Radiology registry (www.bsir.org).
26
![Page 27: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/27.jpg)
Hindley, J. et al. Am. J. Roentgenol. 2004;183:1713-1719
Woman lying on ExAblate 2000 (InSightec) focused ultrasound system ready to be placed into MRI unit
MRI-guided focused ultrasound (MRgFUS)
27
![Page 28: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/28.jpg)
MRgFUS: outline of procedureClear pathway from the anterior abdominal wall to the
fibroid without passing through the bladder or the bowel Shaved anterior abdomenA urinary catheter is insertedUnsuitable for very large uteri (>24w) or fibroids (>10cm)IV analgesia and conscious sedationMaximum treatment time of 3 hr ; recovery 1-2 daysThermal ablation of selected fibroidReal time MR Thermometry (aiming >55 degrees C)Gadolinium-enhanced MRI performed immediately after
treatment28
![Page 29: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/29.jpg)
Hindley, J. et al. Am. J. Roentgenol. 2004;183:1713-19
AFTER MRgFUS: Non-Perfused Volume (NPV) ratiocalculated from the gadolinium-enhanced MRI performed immediately after treatment
BEFORE
29
![Page 30: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/30.jpg)
MRgFUSFibroid size 20% at 2yr
AUB 60-70%
Higher NPV corresponds to greater fibroid size reduction and symptom relief at 12-month
Fertility Reported-mainly for single fibroid ablations
Secondary treatment ? 30%
Complication rate 10% (pain, vaginal discharge)
•E. A. Stewart et al. Sustained Relief of Leiomyoma Symptoms by Using Focused Ultrasound Surgery. Obstet. Gynecol., August 1, 2007; 110(2): 279 - 287.•Z. M. Lenard et al. Uterine Leiomyomas: MR Imaging-guided Focused Ultrasound Surgery--Imaging Predictors of Success. Radiology, Oct 1, 2008; 249(1): 187 – 194•Rabinovici J et al. Pregnancy outcome after magnetic resonance–guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertility &Sterility, In Press, 200830
![Page 31: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/31.jpg)
ConclusionsMultiple treatment options existAdvances in hysteroscopyNew interventional technologies show early promise
However, • Several unanswered questions• Urgent need for further research• Need for increased consumer input
31
![Page 32: Fibroid2](https://reader034.vdocument.in/reader034/viewer/2022042716/55a733531a28ab7b028b4832/html5/thumbnails/32.jpg)
32
CONSUMER WEBSITE UNDER DEVELOPMENT